People · Operator
Named in public records as an officer, director or promoter · active 2019–2021 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| AbSci Corp | — | Biotechnology | Series D+ | $221.0M | $4.1B | 2020 |
| BioEclipse Therapeutics, Inc. | — | Biotechnology | Series A | $10.1M | $366.1M | 2019 |
Gregory Schiffman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Gregory Schiffman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Biao He | 1 | 5 |
| Elona Baum | 1 | 5 |
| Stephen Thau | 1 | 4 |
| Catherine Sohn | 1 | 3 |
| Mark Frohlich | 1 | 3 |
| Daniel Gold | 1 | 2 |
| V. Bryan Lawlis | 1 | 2 |
| Zach Jonasson | 1 | 2 |
| Gustavo Mahler | 1 | 2 |
| Amrit Bryan Nagpal | 1 | 1 |
| Lawrence McClure | 1 | 1 |
| Shelley Klassen | 1 | 1 |
| Bryan Lawliss | 1 | 1 |
| Zach Zach Jonasson | 1 | 1 |
| Pamela Reilly Contag | 1 | 1 |
| Benjamin Carter | 1 | 1 |
| Pamela Contag | 1 | 1 |
| Bryan Lawlis | 1 | 1 |
| Phil Barish | 1 | 1 |
| Sean McClain | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.